Close

Production & Manufacturing

Aspen proposes to acquire GSK’s thrombosis brands and NDB site

Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has received a proposal from Aspen Global and Aspen Pharmacare Holdings for its thrombosis brands and Notre-Dame de Bondeville (NDB) site. The offer includes the transfer of GSK's...

Medicago wins European patent for influenza virus-like particles in plants

The European Patent Office (EPO) has granted Medicago a patent protecting exclusive rights to produce influenza virus-like particles (VLPs) in plants through July 2028. Patent titled 'Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a...

Bionomics commences BNC10 manufacturing activities

Australia-based international biotechnology company Bionomics has commenced manufacturing activities for anti-cancer stem cell candidate BNC10. Lonza will manufacture BNC101 at Slough facility in the UK. Bionomics CEO and managing director Dr Deborah Rathjen said,...

DSM, DecImmune collaborate to develop N2 pathway blocking antibody

DSM Pharmaceutical Products has entered into collaboration with venture capital funded DecImmune Therapeutics of Cambridge, US. As per the agreement, DSM will initiate the development activities for DecImmune's lead monoclonal antibody program. DecImmune is...

Sunshine looking for CMOs for breast cancer drug Adva-27a manufacturing

Sunshine Biopharma has started discussions with contract manufacturing organizations (CMOs) for the production of its multidrug-resistant breast cancer drug, Adva-27a. The company is looking for 1kg of Adva-27a for the forthcoming IND-Enabling animal toxicity...

Qualicaps to invest $26m for Whitsett facility expansion

Pharmaceutical manufacturer Qualicaps will invest $26m to expand its facility in Whitsett, North Carolina in the US. Under the expansion plans, the firm will also add additional 100,000 ft² building space. The project will...

Bone Therapeutics to build new manufacturing facility in Belgium

Biopharmaceutical company Bone Therapeutics has announced that it has made a €10m investment in Skeletal Cell Therapy Support (SCTS) to build a new manufacturing facility at Gosselies Scientific Park near Brussels in Belgium. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read